Pharmagreen Biotech's Days Sales Outstanding for the
three
months ended in Jun. 2023 was 91.25.
Pharmagreen Biotech's Days Inventory for the
three
months ended in Jun. 2023 was 0.
Pharmagreen Biotech's Days Payable for the
three
months ended in Jun. 2023 was 0.
Therefore, Pharmagreen Biotech's Cash Conversion Cycle (CCC) for the
three
months ended in Jun. 2023 was 91.25.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Pharmagreen Biotech Cash Conversion Cycle Related Terms
Pharmagreen Biotech Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Pharmagreen Biotech's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHBI vs DVLP, CSTF, BLMS: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmagreen Biotech Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Pharmagreen Biotech's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Pharmagreen Biotech's Cash Conversion Cycle for the fiscal year that ended in Sep. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmagreen Biotech (PHBI) has a Cash Conversion Cycle of 91.25 as of Jun. 2023. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Pharmagreen Biotech and its competitors.
Is Pharmagreen Biotech's Cash Conversion Cycle too high?
Pharmagreen Biotech's current Cash Conversion Cycle is 91.25. The Drug Manufacturers industry median Cash Conversion Cycle is 145.82. Pharmagreen Biotech's value of 91.25 is 37.4% below this industry median.
How does Pharmagreen Biotech's Cash Conversion Cycle compare to DVLP and CSTF?
Pharmagreen Biotech's Cash Conversion Cycle of 91.25 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.82. Pharmagreen Biotech's value of 91.25 is 37.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.82, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmagreen Biotech's current Cash Conversion Cycle of 91.25 is 37.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Pharmagreen Biotech and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmagreen Biotech's current Cash Conversion Cycle is 91.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmagreen Biotech stock overvalued right now?
Pharmagreen Biotech (PHBI) has a current Cash Conversion Cycle of 91.25. The current Cash Conversion Cycle is 91.25 and 37.4% below the Drug Manufacturers industry median of 145.82. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Pharmagreen Biotech (PHBI), the current Cash Conversion Cycle is 91.25 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHBI has been successfully added to your 